8gv1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (09:53, 9 October 2024) (edit) (undo)
 
Line 8: Line 8:
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8gv1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8gv1 OCA], [https://pdbe.org/8gv1 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8gv1 RCSB], [https://www.ebi.ac.uk/pdbsum/8gv1 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8gv1 ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8gv1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8gv1 OCA], [https://pdbe.org/8gv1 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8gv1 RCSB], [https://www.ebi.ac.uk/pdbsum/8gv1 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8gv1 ProSAT]</span></td></tr>
</table>
</table>
-
<div style="background-color:#fffaf0;">
 
-
== Publication Abstract from PubMed ==
 
-
Efficient production of bispecific antibodies (BsAbs) in single mammalian cells is essential for basic research and industrial manufacturing. However, preventing unwanted pairing of heavy chains (HCs) and light chains (LCs) is a challenging task. To address this, we created an engineering technology for preferential cognate HC/LC and HC/HC paring called FAST-Ig (Four-chain Assembly by electrostatic Steering Technology - Immunoglobulin), and applied it to NXT007, a BsAb for the treatment of hemophilia A. We introduced charged amino-acid substitutions at the HC/LC interface to facilitate the proper assembly for manufacturing a standard IgG-type BsAb. We generated CH1/CL interface-engineered antibody variants that achieved &gt; 95% correct HC/LC pairing efficiency with favorable pharmacological properties and developability. Among these, we selected a design (C3) that allowed us to separate the mis-paired species with an unintended pharmacological profile using ion-exchange chromatography. Crystal structure analysis demonstrated that the C3 design did not affect the overall structure of both Fabs. To determine the final design for HCs-heterodimerization, we compared the stability of charge-based and knobs into hole-based Fc formats in acidic conditions and selected the more stable charge-based format. FAST-Ig was also applicable to stable CHO cell lines for industrial production and demonstrated robust chain pairing with different subclasses of parent BsAbs. Thus, it can be applied to a wide variety of BsAbs both preclinically and clinically.
 
- 
-
Efficient production of bispecific antibody by FAST-Ig(TM) and its application to NXT007 for the treatment of hemophilia A.,Koga H, Yamano T, Betancur J, Nagatomo S, Ikeda Y, Yamaguchi K, Nabuchi Y, Sato K, Teranishi-Ikawa Y, Sato M, Hirayama H, Hayasaka A, Torizawa T, Haraya K, Sampei Z, Shiraiwa H, Kitazawa T, Igawa T, Kuramochi T MAbs. 2023 Jan-Dec;15(1):2222441. doi: 10.1080/19420862.2023.2222441. PMID:37339067<ref>PMID:37339067</ref>
 
- 
-
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 
-
</div>
 
-
<div class="pdbe-citations 8gv1" style="background-color:#fffaf0;"></div>
 
-
== References ==
 
-
<references/>
 
__TOC__
__TOC__
</StructureSection>
</StructureSection>

Current revision

Crystal structure of anti-FX IgG fab with FAST-Ig mutations

PDB ID 8gv1

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools